Other

Chemgenes Corporation

Stanley J Szymanski, Jr

Suresh C Srivastava

Sant K Srivastav

The invention involves various embodiments of a method for treating a human being for a condition associated with (1) seizures, myoclonic seizures, epilepsy, refractory epilepsy, hyperkinetic movements or tremors of hands or feet, (2) a state of ataxia, (3) accumulation of neuronal autofluorescent storage bodies in lysosomes or neurons, or regression of motor development, and (4) low alertness, dementia or mental retardation. The method involves administering a therapeutically effective salt of N-6-trimethyl-L-lysine.

Method of treating a human being for a class of neurological defects and seizure disorders

The invention provides a method of synthesis of N-6-trimethyl-L-lysine (TML) derivative compounds for potential treatment of disorders resulting from deficiencies in the TML-carnitine pathway. The invention also provides a method of purification of TML and TML derivative compounds. The treatment of conditions of the diseases late infantile neuronal ceroid lipofuscinosis (LINCL) and neuronal ceroid lipofuscinosis (NCL) with TML were shown in the original parent application.

Method of synthesis and purification of N-6-trimethyl-L-lysine and derivative compounds

The invention involves various embodiments of a method for treating a human being for a condition associated with (1) a clinical state of impairment of carnitine or carnitine esters, or decreased fatty acid metabolism, (2) low energy production or lower ATP production, (3) clinical hyperammonemia, and (4) clinically high pyruvate levels resulting from a deficiency in the biosynthesis of carnitine. The method involves administering a therapeutically effective salt of N-6-trimethyl-L-lysine.

Method of treating a human being for a class of metabolic defects and energy production disorders

The invention provides compositions for and methods of treating a number of disorders. In one embodiment, the invention provides a method of treating a wide range of conditions by administering to a human being in need of such treatment, a therapeutically effective amount of (a) N-6-trimethyl-L-lysine of at least 98% purity, (b) a prodrug thereof, (c) an aliphatic chain derivative thereof, (d) an ester derivative thereof, (e) an amide derivative thereof, or (f) a pharmaceutically acceptable salt of said N-6-trimethyl-L-lysine or said prodrug.

Growing community of inventors

Sewickley, PA, United States of America

Stanley J Szymanski, Jr